October 10, 2024 04:51 PM EDT
Pharma
FDA+

FDA ap­proves Roche's new treat­ment for sub­set of breast can­cer pa­tients

Katherine Lewin

News Reporter

The FDA has ap­proved Roche’s in­avolis­ib plus Pfiz­er’s Ibrance and ful­ves­trant in a sub­type of breast can­cer over a month be­fore the tar­get ac­tion date …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: How an ac­ci­den­tal email tipped Pfiz­er off to an ac­tivist in­vestor’s plan

Eli Lil­ly inks an­oth­er obe­si­ty pact, dou­bling down on small Swiss part­ner

Sev­en pa­tients di­ag­nosed with blood can­cer af­ter Skysona treat­ment, new da­ta show

Star­board launch­es first sal­vo in Pfiz­er fight, al­leg­ing ex-CEO, CFO were pres­sured to flip

Grit­stone files for bank­rupt­cy, says it could forge a trans­ac­tion as ear­ly as this month to keep R&D go­ing

Sen. War­ren urges FTC to ‘care­ful­ly scru­ti­nize’ No­vo-Catal­ent deal over com­pe­ti­tion con­cerns

A service from the Financial Times